News Releases

<< Back
Mar 07, 2018

SCYNEXIS to Present at the 30th Annual ROTH Conference

JERSEY CITY, N.J., March 7, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections, today announced that the Company will present at the 30th Annual ROTH Conference at the Ritz Carlton Laguna Niguel in Dana Point on Tuesday, March 13, 2018 at 7:30 a.m. PT.

A live webcast will be available on the Investors section of the Company's website: A replay of the presentation will be available approximately two hours after the event and will be available for two weeks following the presentation.

SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas. The Company's lead product candidate, SCY-078, is a novel IV/oral antifungal agent in Phase 2 clinical and preclinical development for the treatment of several serious and life-threatening invasive fungal infections caused by Candida and Aspergillus species. For more information, visit


Investor Relations
Susan Kim
Argot Partners
Tel: 212-203-4433

Media Relations
George E. MacDougall
MacDougall Biomedical Communications
Tel: 781-235-3093 


Cision View original content: